Compare TEX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | BLTE |
|---|---|---|
| Founded | 1933 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.5B |
| IPO Year | 1994 | 2021 |
| Metric | TEX | BLTE |
|---|---|---|
| Price | $64.45 | $175.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $68.80 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.1M | 148.5K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $5,421,000,000.00 | N/A |
| Revenue This Year | $47.68 | N/A |
| Revenue Next Year | $6.81 | $492.11 |
| P/E Ratio | $19.02 | ★ N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $33.13 | $53.60 |
| 52 Week High | $71.50 | $200.00 |
| Indicator | TEX | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 56.90 |
| Support Level | $58.60 | $167.80 |
| Resistance Level | $70.58 | $196.14 |
| Average True Range (ATR) | 2.33 | 8.50 |
| MACD | 0.79 | 2.26 |
| Stochastic Oscillator | 93.53 | 77.37 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.